Application of FcRn binding assays to guide mAb development

Drug Metabolism and Disposition

Volumn 42, Issue 11, 2014, Pages 1867-1872

  Datta Mannan, Amita ^a   Wroblewski, Victor J ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG ANTIBODY; FC RECEPTOR; IMMUNOGLOBULIN G; INTERLEUKIN 6 RECEPTOR; MONOCLONAL ANTIBODY; NEONATAL FC RECEPTOR; OKT 4; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; SERINE PROTEINASE; UNCLASSIFIED DRUG; FC RECEPTOR, NEONATAL; HLA ANTIGEN CLASS 1; PROTEIN BINDING;

ANTIBODY ENGINEERING; ANTIGEN ANTIBODY COMPLEX; BINDING AFFINITY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG ELIMINATION; ELIMINATION HALF-LIFE; ENDOSOME; HUMAN; INTERNALIZATION; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN ENGINEERING; RECEPTOR BINDING ASSAY; SHORT SURVEY; SURFACE PLASMON RESONANCE; ANIMAL; METABOLISM; PHARMACOKINETICS;

ANIMALS; ANTIBODIES, MONOCLONAL; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; PHARMACOKINETICS; PROTEIN BINDING; RECEPTORS, FC;

EID: 84930888139     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.114.059089     Document Type: Short Survey

References (43)

1. Bumbaca D, Boswell CA, Fielder PJ, and Khawli LA (2012) Physiochemical and biochemical factors influencing the pharmacokinetics of antibody therapeutics. AAPS J 14:554-558.
2. Chan AC and Carter PJ (2010) Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol 10:301-316.
3. Chaparro-Riggers J, Liang H, DeVay RM, Bai L, Sutton JE, Chen W, Geng T, Lindquist K, Casas MG, and Boustany LM, et al. (2012) Increasing serum half-life and extending cholesterol lowering in vivo by engineering antibody with pH-sensitive binding to PCSK9. J Biol Chem 287:11090-11097.
4. Christianson GJ, Brooks W, Vekasi S, Manolfi EA, Niles J, Roopenian SL, Roths JB, Rothlein R, and Roopenian DC (1997) Beta 2-microglobulin-deficient mice are protected from hypergammaglobulinemia and have defective antibody responses because of increased IgG catabolism. J Immunol 159:4781-4792.
5. Dall'Acqua WF, Woods RM, Ward ES, Palaszynski SR, Patel NK, Brewah YA, Wu H, Kiener PA, and Langermann S (2002) Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences. J Immunol 169:5171-5180.
6. Dall'Acqua WF, Kiener PA, and Wu H (2006) Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem 281:23514-23524.
7. Datta-Mannan A, Witcher DR, Tang Y, Watkins J, Jiang W, and Wroblewski VJ (2007a) Humanized IgG1 variants with differential binding properties to the neonatal Fc receptor: relationship to pharmacokinetics in mice and primates. Drug Metab Dispos 35:86-94.
8. Datta-Mannan A, Witcher DR, Tang Y, Watkins J, and Wroblewski VJ (2007b) Monoclonal antibody clearance. Impact of modulating the interaction of IgG with the neonatal Fc receptor. J Biol Chem 282:1709-1717.
9. Datta-Mannan A, Chow CK, Dickinson C, Driver D, Lu J, Witcher DR, and Wroblewski VJ (2012a) FcRn affinity-pharmacokinetic relationship of five human IgG4 antibodies engineered for improved in vitro FcRn binding properties in cynomolgus monkeys. Drug Metab Dispos 40:1545-1555.
10. Datta-Mannan A, Witcher DR, Lu J, and Wroblewski VJ (2012b) Influence of improved FcRn binding on the subcutaneous bioavailability of monoclonal antibodies in cynomolgus monkeys. MAbs 4:267-273.
11. Deng R, Loyet KM, Lien S, Iyer S, DeForge LE, Theil F-P, Lowman HB, Fielder PJ, and Prabhu S (2010) Pharmacokinetics of humanized monoclonal anti-tumor necrosis factor-α antibody and its neonatal Fc receptor variants in mice and cynomolgus monkeys. Drug Metab Dispos 38:600-605.
12. Ghetie V and Ward ES (1997) FcRn: the MHC class I-related receptor that is more than an IgG transporter. Immunol Today 18:592-598.
13. Ghetie V, Hubbard JG, Kim JK, Tsen MF, Lee Y, and Ward ES (1996) Abnormally short serum half-lives of IgG in beta 2-microglobulin-deficient mice. Eur J Immunol 26:690-696.
14. Ghetie V, Popov S, Borvak J, Radu C, Matesoi D, Medesan C, Ober RJ, and Ward ES (1997) Increasing the serum persistence of an IgG fragment by random mutagenesis. Nat Biotechnol 15:637-640.
15. Goebl NA, Babbey CM, Datta-Mannan A, Witcher DR, Wroblewski VJ, and Dunn KW (2008) Neonatal Fc receptor mediates internalization of Fc in transfected human endothelial cells. Mol Biol Cell 19:5490-5505.
16. Gurbaxani B, Dela Cruz LL, Chintalacharuvu K, and Morrison SL (2006) Analysis of a family of antibodies with different half-lives in mice fails to find a correlation between affinity for FcRn and serum half-life. Mol Immunol 43:1462-1473.
17. Gurbaxani B, Dostalek M, and Gardner I (2013) Are endosomal trafficking parameters better targets for improving mAb pharmacokinetics than FcRn binding affinity? Mol Immunol 56:660-674.
18. Hinton PR, Johlfs MG, Xiong JM, Hanestad K, Ong KC, Bullock C, Keller S, Tang MT, Tso JY, and Vásquez M, et al. (2004) Engineered human IgG antibodies with longer serum half-lives in primates. J Biol Chem 279:6213-6216.
19. Hinton PR, Xiong JM, Johlfs MG, Tang MT, Keller S, and Tsurushita N (2006) An engineered human IgG1 antibody with longer serum half-life. J Immunol 176:346-356.
20. Igawa T, Ishii S, Tachibana T, Maeda A, Higuchi Y, Shimaoka S, Moriyama C, Watanabe T, Takubo R, and Doi Y, et al. (2010a) Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization. Nat Biotechnol 28:1203-1207.
21. Igawa T, Tsunoda H, Tachibana T, Maeda A, Mimoto F, Moriyama C, Nanami M, Sekimori Y, Nabuchi Y, and Aso Y, et al. (2010b) Reduced elimination of IgG antibodies by engineering the variable region. Protein Eng Des Sel 23:385-392.
22. Igawa T, Maeda A, Haraya K, Tachibana T, Iwayanagi Y, Mimoto F, Higuchi Y, Ishii S, Tamba S, and Hironiwa N, et al. (2013) Engineered monoclonal antibody with novel antigen-sweeping activity in vivo. PLoS ONE 8:e63236.
23. Khawli LA, Goswami S, Hutchinson R, Kwong ZW, Yang J, Wang X, Yao Z, Sreedhara A, Cano T, and Tesar D, et al. (2010) Charge variants in IgG1: Isolation, characterization, in vitro binding properties and pharmacokinetics in rats. MAbs 2:613-624.
24. Mathur A, Arora T, Liu L, Crouse-Zeineddini J, and Mukku V (2013) Qualification of a homogeneous cell-based neonatal Fc receptor (FcRn) binding assay and its application to studies on Fc functionality of IgG-based therapeutics. J Immunol Methods 390:81-91.
25. Ober RJ, Martinez C, Lai X, Zhou J, and Ward ES (2004a) Exocytosis of IgG as mediated by the receptor, FcRn: an analysis at the single-molecule level. Proc Natl Acad Sci USA 101:11076-11081.
26. Ober RJ, Martinez C, Vaccaro C, Zhou J, and Ward ES (2004b) Visualizing the site and dynamics of IgG salvage by the MHC class I-related receptor, FcRn. J Immunol 172:2021-2029.
27. Prabhat P, Ram S, Ward ES, and Ober RJ (2004) Simultaneous imaging of different focal planes in fluorescence microscopy for the study of cellular dynamics in three dimensions. IEEE Trans Nanobioscience 3:237-242.
28. Presta LG (2008) Molecular engineering and design of therapeutic antibodies. Curr Opin Immunol 20:460-470.
29. Raghavan M, Bonagura VR, Morrison SL, and Bjorkman PJ (1995) Analysis of the pH dependence of the neonatal Fc receptor/immunoglobulin G interaction using antibody and receptor variants. Biochemistry 34:14649-14657.
30. Reichert JM (2010) Metrics for antibody therapeutics development. MAbs 2:695-700.
31. Robbie GJ, Criste R, Dall'acqua WF, Jensen K, Patel NK, Losonsky GA, and Griffin MP (2013) A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults. Antimicrob Agents Chemother 57:6147-6153.
32. Roopenian DC and Akilesh S (2007) FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 7:715-725.
33. Suzuki T, Ishii-Watabe A, Tada M, Kobayashi T, Kanayasu-Toyoda T, Kawanishi T, and Yamaguchi T (2010) Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR. J Immunol 184:1968-1976.
34. Tabrizi MA and Roskos LK (2007) Preclinical and clinical safety of monoclonal antibodies. Drug Discov Today 12:540-547.
35. Wang W, Lu P, Fang Y, Hamuro L, Pittman T, Carr B, Hochman J, and Prueksaritanont T (2011a) Monoclonal antibodies with identical Fc sequences can bind to FcRn differentially with pharmacokinetic consequences. Drug Metab Dispos 39:1469-1477.
36. Wang W, Vlasak J, Li Y, Pristatsky P, Fang Y, Pittman T, Roman J, Wang Y, Prueksaritanont T, and Ionescu R (2011b) Impact of methionine oxidation in human IgG1 Fc on serum half-life of monoclonal antibodies. Mol Immunol 48:860-866.
37. Ward ES, Zhou J, Ghetie V, and Ober RJ (2003) Evidence to support the cellular mechanism involved in serum IgG homeostasis in humans. Int Immunol 15:187-195.
38. Ward ES, Martinez C, Vaccaro C, Zhou J, Tang Q, and Ober RJ (2005) From sorting endosomes to exocytosis: association of Rab4 and Rab11 GTPases with the Fc receptor, FcRn, during recycling. Mol Biol Cell 16:2028-2038.
39. Weiner LM, Surana R, and Wang S (2010) Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol 10:317-327.
40. West AP, Jr and Bjorkman PJ (2000) Crystal structure and immunoglobulin G binding properties of the human major histocompatibility complex-related Fc receptor(,). Biochemistry 39:9698-9708.
41. Yeung YA, Leabman MK, Marvin JS, Qiu J, Adams CW, Lien S, Starovasnik MA, and Lowman HB (2009) Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates. J Immunol 182:7663-7671.
42. Yeung YA, Wu X, Reyes AE, 2nd, Vernes JM, Lien S, Lowe J, Maia M, Forrest WF, Meng YG, and Damico LA, et al. (2010) A therapeutic anti-VEGF antibody with increased potency independent of pharmacokinetic half-life. Cancer Res 70:3269-3277.
43. Zheng Y, Scheerens H, Davis JC, Jr, Deng R, Fischer SK, Woods C, Fielder PJ, and Stefanich EG (2011) Translational pharmacokinetics and pharmacodynamics of an FcRn-variant anti-CD4 monoclonal antibody from preclinical model to phase I study. Clin Pharmacol Ther 89:283-290.